Last reviewed · How we verify
The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients (PD QOL)
The study will examine 30 patients between ages 50-80, newly diagnosed with early-stage Parkinson's Disease. Patients will be randomized to receive either Citalopram or Carbidopa-levodopa. The investigators' primary outcome measure will be change in quality of life over a prospective period of 6 months. Secondary outcome measures will include change in mood state and motor symptoms, as well as comparison of improvement between two treatments. Primary investigators would also like to collect quantitative electroencephalogram (qEEG) recordings, which is a reading of brain activity as an additional interest of this study. Primary investigators will assess the qEEG recordings for electrophysiological findings before and after interventions.
Details
| Lead sponsor | Western University, Canada |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 30 |
| Start date | 2021-01 |
| Completion | 2022-01 |
Conditions
- Parkinson Disease
- Depression
Interventions
- Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
- Citalopram
Primary outcomes
- Difference between two arms in change of Short Form-36 (SF-36) scores — 6 months
Using a 6-month Randomized Controlled Trial (RCT) intervention study, assess whether Citalopram can improve Quality Of Life (QOL) significantly more than carbidopa-levodopa in early stage Parkinson's disease. This will be measured as a change in SF-36 scores, where the lower scores are associated with more disability. Scores range from 0-100.